Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Self-amplifying ribonucleic acid vaccine - BioNTech/Pfizer

Next Previous
Drug Profile

Self-amplifying ribonucleic acid vaccine - BioNTech/Pfizer

Alternative Names: PF-07836391 Influenza saRNA; PF-07836394 Influenza saRNA; PF-07836395 Influenza saRNA; PF-07836396 Influenza saRNA; PF-07852352 Influenza saRNA 1; PF-07867246 Influenza saRNA; PF-07871987 Influenza saRNA; PF-07914705 Influenza saRNA; PF-07915048 Influenza saRNA

Latest Information Update: 26 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Class Influenza virus vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 04 Aug 2023 Pfizer completes a phase I trial in Influenza virus infections (Prevention) in USA (IM) (NCT05227001)
  • 28 Apr 2022 Phase-I clinical trials in Influenza virus infections (Prevention) in USA (IM) (NCT05227001)
  • 09 Feb 2022 Pfizer plans a phase I trial in Influenza virus infections (Prevention) (IM, Injection), in April 2022 (NCT05227001)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top